U.S. Markets open in 4 hrs 51 mins

Urovant Sciences Ltd. (UROV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.21-0.23 (-2.73%)
At close: 4:00PM EDT

Urovant Sciences Ltd.

11-12 Street, James’s Square
Suite 1 3rd Floor
London SW1Y 4LB
United Kingdom
44 20 7400 3347

Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Mr. James A. Robinson Jr.Pres, CEO & Director1.07MN/A1970
Mr. Ajay BansalCFO & Sr. VP of Bus. Devel.558.34kN/A1962
Dr. Cornelia Haag-Molkenteller M.D., Ph.D.Chief Medical Officer of USI629.79kN/A1959
Ms. Christine G. OcampoChief Accounting Officer & Sr. VPN/AN/A1972
Ryan KubotaExec. Director of Investor RelationsN/AN/AN/A
Mr. Bryan E. SmithGen. CounselN/AN/A1979
Dr. David HovlandSr. VP of Global Regulatory AffairsN/AN/AN/A
Mr. Kenton StewartSr. VP of Market AccessN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Corporate Governance

Urovant Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.